Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound

Mechanistic description

Mechanism / pathway

Network-Directed Anti-Amyloid Immunotherapy
→
connectomics

Evidence for (5)

Hub regions show preferential amyloid deposition due to high activity-dependent amyloid production

PMID:19219025
tFUS-mediated BBB opening enables targeted delivery to specific brain regions

PMID:29422609
Network-level degeneration in AD follows connectivity patterns - hubs are vulnerable

PMID:20644199
Exablate Neuro FDA-approved for essential tremor/PD - regulatory pathway exists

PMID:31046252
Amyloid clearance (60-80% PET reduction) achievable with antibodies

PMID:31881167

Evidence against (5)

tFUS spatial precision limited to 2-5mm - sub-centimeter hub targeting unachievable

PMID:35101508
Even robust amyloid clearance (lecanemab/donanemab) produces only 27-35% clinical slowing

PMID:31881167
Amyloid clearance fails to restore functional connectivity to normal levels

PMID:34019835
FcRn-mediated IgG recycling provides substantial brain penetration without tFUS

PMID:31881167
40-60% enhancement prediction lacks empirical basis - unsubstantiated numerical claim

Evidence matrix

5 supporting 5 contradicting

47% posterior support

Supporting

Hub regions show preferential amyloid deposition due to high activity-dependent amyloid production PMID:19219025
tFUS-mediated BBB opening enables targeted delivery to specific brain regions PMID:29422609
Network-level degeneration in AD follows connectivity patterns - hubs are vulnerable PMID:20644199
Exablate Neuro FDA-approved for essential tremor/PD - regulatory pathway exists PMID:31046252
Amyloid clearance (60-80% PET reduction) achievable with antibodies PMID:31881167

Contradicting

tFUS spatial precision limited to 2-5mm - sub-centimeter hub targeting unachievable PMID:35101508
Even robust amyloid clearance (lecanemab/donanemab) produces only 27-35% clinical slowing PMID:31881167
Amyloid clearance fails to restore functional connectivity to normal levels PMID:34019835
FcRn-mediated IgG recycling provides substantial brain penetration without tFUS PMID:31881167
40-60% enhancement prediction lacks empirical basis - unsubstantiated numerical claim

Bayesian persona consensus

47% posterior support

1 signal · 0 for / 1 against · agreement 0%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-9553243b

BibTeX

@misc{scidex_hypothesis_h9553243,
  title        = {Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-9553243b},
  note         = {SciDEX artifact hypothesis:h-9553243b}
}